// App-Quantinova.ai

: Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Researchers

Presenter

  • Matthew Raymond Smith

Principal Investigators

  • Shahneen Kaur Sandhu

  • William Kevin Kelly

  • Howard I. Scher

  • Eleni Efstathiou

  • Primo Lara

  • Evan Y. Yu

  • Daniel J. George

  • Kim N. Chi

  • Jason Summa

  • Nishi Kothari

  • Xin Zhao

  • Byron M. Espina

  • Deborah S. Ricci

  • Jason S. Simon

  • Namphuong Tran

  • Karim Fizazi

Medical Centers

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Thomas Jefferson University, Philadelphia, PA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, Houston, TX

  • University of California, Davis Comprehensive Cancer Center, Sacramento, CA

  • University of Washington, Seattle, WA

  • Duke Cancer Institute, Durham, NC

  • University of British Columbia, BC Cancer Research Centre, Vancouver, Canada

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, San Diego, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • United States

  • Australia

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

  • Genetic Disorder

  • Nephrology

  • Blood/haematological Diseases

Disease

  • Metastatic castration-resistant prostate cancer

  • Fanconi anemia, complementation group A

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • checkpoint kinase 2

  • Circulating tumor cells

  • Prostate specific antigen

  • Fanconi anaemia, complementation group A

  • Histone Deacetylase 2

  • Partner and localizer of BRCA2

  • BRCA1 interacting protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Niraparib

  • taxane

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • NA

Study Id's

  • NCT02854436

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved